The human interferon-alpha species and hybrid proteins.

Abstract:

:Ten years of interferon (IFN) therapy have followed the approval of this agent by the US Food and Drug Administration on June 5, 1986. As the first biotherapeutic approved, IFN-alpha paved the way for the many new biotherapeutics. Regardless of this long history, however, we have just touched the surface of understanding the multitude of human IFNs. This report reviews the history of the purification of human leukocyte IFN and key aspects of our current state of knowledge of human leukocyte IFN genes and proteins.

journal_name

Semin Oncol

journal_title

Seminars in oncology

authors

Pestka S

subject

Has Abstract

pub_date

1997-06-01 00:00:00

pages

S9-4-S9-17

issue

3 Suppl 9

eissn

0093-7754

issn

1532-8708

journal_volume

24

pub_type

杂志文章,评审
  • Monoclonal antibody treatment of solid tumors: a coming of age.

    abstract::Over the past 5 years there has been a renewed interest in the use of monoclonal antibodies and immunoconjugates in the treatment of nonhematologic malignancies. This enthusiasm has stemmed from advances in recombinant technology allowing for the production of chimeric and humanized antibodies, from Food and Drug Admi...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Murray JL

    更新日期:2000-12-01 00:00:00

  • Photodynamic therapy for lung cancer and malignant pleural mesothelioma.

    abstract::Photodynamic therapy (PDT) is a form of non-ionizing radiation therapy that uses a drug, called a photosensitizer, combined with light to produce singlet oxygen ((1)O2) that can exert anti-cancer activity through apoptotic, necrotic, or autophagic tumor cell death. PDT is increasingly being used to treat thoracic mali...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2014.09.017

    authors: Simone CB 2nd,Cengel KA

    更新日期:2014-12-01 00:00:00

  • Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46).

    abstract::In studies conducted by the Eastern Cooperative Oncology Group, treatment with either paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) or carboplatin was associated with an improvement in 1-year survival in patients with stage IV non-small cell lung cancer (NSCLC). Based on these findings, a phase II tr...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Johnson DH,Paul DM,Hande KR,DeVore R

    更新日期:1996-12-01 00:00:00

  • Challenges and opportunities for Erlotinib (Tarceva): what does the future hold?

    abstract::The development of targeted agents has brought new opportunities and extraordinary therapeutic challenges to cancer therapy. Several agents that inhibit epidermal growth factor receptor (HER1/EGFR) tyrosine kinase have been developed and are advanced in their clinical development. Preclinical and clinical data show th...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Hortobagyi GN,Sauter G

    更新日期:2003-06-01 00:00:00

  • Hepatic arterial chemotherapy in metastatic colorectal patients.

    abstract::Hepatic metastases are a major cause of morbidity and mortality for patients with colorectal cancer (CRC). The rationale for hepatic arterial chemotherapy has both an anatomical and pharmacological basis. Several randomized clinical studies of fluoropyrimidine showed higher response rates in all trials when the drug w...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Kemeny NE,Ron IG

    更新日期:1999-10-01 00:00:00

  • Preclinical models of cardiac protection and testing for effects of dexrazoxane on doxorubicin antitumor effects.

    abstract::The ability of dexrazoxane (DEX) to protect against doxorubicin (DOX)-induced cardiomyopathy has been demonstrated in mice, normotensive and hypertensive rats, rabbits, dogs, swine, and humans. These animal models of DOX-induced cardiomyopathy were found to be highly predictive of DEX activity clinically. In mice admi...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Imondi AR

    更新日期:1998-08-01 00:00:00

  • Mammalian target of rapamycin inhibitors in renal cell carcinoma: current status and future applications.

    abstract::Significant achievements in the basic sciences have led to a greater knowledge of the underlying signaling pathways in renal cell cancer (RCC), including the mammalian target of rapamycin (mTOR) pathway (phosphoinositide 3-kinase/Akt pathway). The mTOR pathway has a central role in the regulation of cell growth and in...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2006.06.002

    authors: Pantuck AJ,Thomas G,Belldegrun AS,Figlin RA

    更新日期:2006-10-01 00:00:00

  • Carcinoma of the uterine cervix: current status and future directions.

    abstract::Based on rigorous interpretation of current evidence, systemic therapy has two roles in the management of carcinoma of the uterine cervix. In patients with advanced or recurrent disease, single-agent chemotherapy constitutes the treatment of choice. The most extensively studied agents are the platinum compounds. Eithe...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Thigpen T,Vance RB,Khansur T

    更新日期:1994-04-01 00:00:00

  • The root causes of pharmacodynamic assay failure.

    abstract::Robust pharmacodynamic assay results are valuable for informing go/no-go decisions about continued development of new anti-cancer agents and for identifying combinations of targeted agents, but often pharmacodynamic results are too incomplete or variable to fulfill this role. Our experience suggests that variable reag...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2016.06.006

    authors: Ferry-Galow KV,Makhlouf HR,Wilsker DF,Lawrence SM,Pfister TD,Marrero AM,Bigelow KM,Yutzy WH,Ji JJ,Butcher DO,Gouker BA,Kummar S,Chen AP,Kinders RJ,Parchment RE,Doroshow JH

    更新日期:2016-08-01 00:00:00

  • Single-agent activity of gemcitabine in advanced non-small cell lung cancer.

    abstract::Gemcitabine, a novel nucleoside analog, shows reproducible response rates of 20% and above in single-agent studies in non-small cell lung cancer. In the phase II studies reported, chemotherapy-naive patients received gemcitabine (starting doses, 800 to 1,250 mg/ m2) as a single agent on days 1, 8, and 15 of a 28-day c...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Le Chevalier T

    更新日期:1996-10-01 00:00:00

  • Molecular diagnostics in follicular non-Hodgkin's lymphoma: a review.

    abstract::Follicular lymphoma is a low-grade, indolent non-Hodgkin's lymphoma characterized by the presence of the t(14;18) translocation. The detection of this translocation using polymerase chain reaction techniques has been increasingly studied. However, the diagnostic and prognostic value of detecting t(14;18) rearrangement...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Bordeleau L,Berinstein NL

    更新日期:2000-12-01 00:00:00

  • Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy in stage II and III breast cancer patients: preliminary results of a phase II and pharmacogenomic study.

    abstract::The purpose of this study is to evaluate the efficacy and safety of a biweekly neoadjuvant docetaxel/gemcitabine regimen in patients with histologically confirmed stage II and III breast cancer. In addition, a cDNA microarray study attempted to correlate pretreatment gene-expression profile with clinical and pathologi...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:10.1053/j.seminoncol.2004.03.025

    authors: Estévez LG,Sánchez-Rovira P,Dómine M,León A,Calvo I,Jaén A,Casado V,Rubio G,Daz M,Miró C,Lobo F

    更新日期:2004-04-01 00:00:00

  • Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy.

    abstract::Angiogenesis is required for multistage carcinogenesis. The inducible enzyme cyclooxygenase-2 (COX-2) is an important mediator of angiogenesis and tumor growth. COX-2 expression occurs in a wide range of preneoplastic and malignant conditions; and the enzyme has been localized to the neoplastic cells, endothelial cell...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.03.040

    authors: Gately S,Li WW

    更新日期:2004-04-01 00:00:00

  • Are sex discordant outcomes in COVID-19 related to sex hormones?

    abstract::COVID-19 has a clear sex disparity in clinical outcome. Globally, infection rates between men and women are similar; however, men are more likely to have more severe disease and are more likely to die. The causes for this disparity are currently under investigation and are most likely multifactorial. Sex hormones play...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2020.06.002

    authors: Strope JD,Chau CH,Figg WD

    更新日期:2020-10-01 00:00:00

  • Obstruction due to malignant tumors.

    abstract::An overview of the causes, the clinical pictures and the management of obstruction in three major organ systems due to primary and secondary malignant neoplasms has been presented. Such obstruction often produces dramatic clinical pictures that require careful, appropriate, and often aggressive therapy if patients are...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Sise JG,Crichlow RW

    更新日期:1978-06-01 00:00:00

  • Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SW0G S9003).

    abstract::We report an update on a prospective observational trial for Waldenstrom's macroglobulinemia (WM) that called for re-registration to treatment with fludarabine (30 mg/m(2)) upon the development of symptomatic or progressive disease. Patients who did not require therapy for more than 1 year (n = 54) could be distinguis...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:10.1053/sonc.2003.50050

    authors: Dhodapkar MV,Jacobson JL,Gertz MA,Crowley JJ,Barlogie B

    更新日期:2003-04-01 00:00:00

  • Small cell carcinoma of the lung: cellular origin and relationship to other neoplasms.

    abstract::Many small cell carcinomas share morphological and physiological characteristics with normal and neoplastic cells of Pearse's APUD series, including pulmonary APUD cells and pulmonary carcinoid tumors. There is very likely more than one type of APUD cell in the lung, and conclusions that small cell carcinomas and carc...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Tischler AS

    更新日期:1978-09-01 00:00:00

  • Evolving concepts in the systemic drug therapy of breast cancer.

    abstract::Experimental and clinical observations of the proliferation of cancer cells and their responses to cytotoxic drugs already have had an impact on the design of anticancer therapies and it is possible that further understanding of the natural history of tumors will enable better treatments to be developed. This review a...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Norton L

    更新日期:1997-08-01 00:00:00

  • Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers.

    abstract::Platinum compounds have long played a role in the treatment of gynecologic cancers. Single-agent cisplatin and carboplatin have shown activity in endometrial cancer, and more recent studies have begun to investigate a variety of new platinum-based combinations. In cervical cancer, chemotherapy is used primarily to tre...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.11.007

    authors: Muggia FM

    更新日期:2004-12-01 00:00:00

  • Clinical experience with denileukin diftitox (ONTAK).

    abstract::Denileukin diftitox (ONTAK; Seragen Inc, San Diego, CA) is a fusion protein designed to direct the cytocidal action of diphtheria toxin to cells that overexpress the IL-2 receptor. The human IL-2 receptor exists in three isoforms: low (CD25), intermediate (CD122/CD132), and high (CD25/CD122/CD132) affinity. The high-a...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2005.12.017

    authors: Foss F

    更新日期:2006-02-01 00:00:00

  • Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer.

    abstract::The availability of subcutaneously (SC) administered amifostine may present an advantage for radioprotectant therapy in head and neck cancer patients. In a randomized phase II trial comparing SC amifostine versus no amifostine in 140 patients undergoing radiation therapy for head and neck, thoracic, or pelvic cancers,...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1053/sonc.2002.37350b

    authors: Anné PR

    更新日期:2002-12-01 00:00:00

  • High-dose therapy for breast cancer.

    abstract::In recent years, the most frequent indication for high-dose autologous stem-cell-supported chemotherapy in the United States has been breast cancer. This approach is applied in "high-risk," early-stage disease as adjuvant treatment, and with either curative or palliative intent in metastatic disease. Among both lay pe...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Hudis CA,Münster PN

    更新日期:1999-02-01 00:00:00

  • The development of busulfan/cyclophosphamide preparative regimens.

    abstract::Bone marrow transplantation (BMT) preparative regimens consisting of busulfan (Bu) and cyclophosphamide (Cy) were developed as an alternative to preparative regimens based on total body irradiation (TBI). Animal studies demonstrated that Bu had a high level of myeloablative and antileukemic activity, but little immuno...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Santos GW

    更新日期:1993-08-01 00:00:00

  • Current antiretroviral therapy and its impact on human immunodeficiency virus-related wasting.

    abstract::Recent improvements in the management of people living with human immunodeficiency virus (HIV) disease in the United States have led to remarkable reductions in HIV-related morbidity and mortality. The Centers for Disease Control and Prevention recently reported substantial reductions in acquired immunodeficiency synd...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Sherer R

    更新日期:1998-04-01 00:00:00

  • Increasing tumor uptake of anticancer drugs with imatinib.

    abstract::Solid malignancies often exhibit high interstitial fluid pressure (IFP), which causes poor uptake of anticancer drugs. While there are several mechanisms that regulate IFP in tumors, activation of platelet-derived growth factor receptor, which is expressed in various cell types within the tumor microenvironment, has b...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.03.036

    authors: Pietras K

    更新日期:2004-04-01 00:00:00

  • Ifosfamide in the treatment of bladder cancer.

    abstract::Although chemotherapy for advanced bladder cancer has historically been based on cisplatin-based combination regimens, the limitations of these regimens both in terms of efficacy and toxicity are now widely appreciated. In response to these limitations, other single agents have been studied, and a number have demonstr...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Roth BJ

    更新日期:1996-06-01 00:00:00

  • Challenges in the management of stage II colon cancer.

    abstract::Approximately one third of patients diagnosed with early-stage colon cancer will present with lymph node involvement (stage III) and about one quarter with transmural bowel wall invasion but negative lymph nodes (stage II). Adjuvant chemotherapy targets micrometastatic disease to improve disease-free (DFS) and overall...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2011.05.005

    authors: Dotan E,Cohen SJ

    更新日期:2011-08-01 00:00:00

  • Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.

    abstract::Relapse following complete remission achieved with a single course of high-dose chemotherapy continues to be the main cause of treatment failure in patients with metastatic breast cancer. A phase I/II trial was initiated that combined the two most active drugs against breast cancer, doxorubicin and paclitaxel (Taxol; ...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Rahman Z,Champlin R,Rondon G,Frye D,Valero V,Mehra R,Hortobagyi G

    更新日期:1997-10-01 00:00:00

  • Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in the treatment of small-cell lung cancer.

    abstract::The discovery that etoposide is one of the most active drugs in small-cell lung cancer (SCLC) led to its incorporation into a number of first-line combination chemotherapy regimens. The cyclophosphamide/doxorubicin/etoposide (CAE) regimen was shown to be as active or more active than other standard regimens in nonrand...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Bunn PA Jr,Greco FA,Einhorn L

    更新日期:1986-09-01 00:00:00

  • Should radiotherapy be standard therapy for brain tumors in the elderly? Cons.

    abstract::Elderly patients with malignant gliomas present unique treatment challenges. Data are limited on the efficacy of various treatment modalities for high-grade gliomas in the elderly patient population, particularly for patients over 70 years of age, and the most appropriate treatment strategies remain a matter of debate...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2003.11.027

    authors: Chinot OL

    更新日期:2003-12-01 00:00:00